Prulifloxacin is an oral prodrug fluoroquinolone, hydrolysed in vivo to its active metabolite ulifloxacin, which inhibits bacterial DNA gyrase and topoisomerase IV to block DNA replication. It offers broad-spectrum coverage for respiratory and urinary tract infections with convenient once-daily dosing. Simson Pharma's reference standard and impurity set support generic manufacturers validating dissolution and assay methods.

Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Prulifloxacin Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.